Home Cart Sign in  
Chemical Structure| 1315330-17-6 Chemical Structure| 1315330-17-6

Structure of TL02-59
CAS No.: 1315330-17-6

Chemical Structure| 1315330-17-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

TL02-59 is a selective Src-family kinase Fgr inhibitor that effectively inhibits other Src family members such as Lyn and Hck. It shows significant anti-proliferative activity in acute myeloid leukemia (AML) research.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of TL02-59

CAS No. :1315330-17-6
Formula : C32H34F3N5O4
M.W : 609.64
SMILES Code : O=C(NC1=CC=C(CN2CCN(CC)CC2)C(C(F)(F)F)=C1)C3=CC=C(C)C(OC4=C5C=C(OC)C(OC)=CC5=NC=N4)=C3
MDL No. :MFCD29991221

Safety of TL02-59

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of TL02-59

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
C57BL/6 mesenchymal stem cells 10 nM 10 days TL02-59 significantly reduced the expression of pro-fibrotic genes (Tgf-beta, Col1a1, 3, 4, 5, 6) in target cells PMC10352363
Mouse primary lung fibroblasts 10 nM 72 h TL02-59 significantly reduced the release of pro-fibrotic chemokines (LIX, CXCL5, CCL5, CXCL2, CCL20, G-CSF, IGFBP-3) from radiation-induced senescent cells PMC10352363
MOLM-14 IC50 6.6 nM 72 h Evaluate the inhibitory effect of TL02-59 on MOLM-14 cell growth PMC6130198
MV4-11 IC50 < 1 nM 72 h Evaluate the inhibitory effect of TL02-59 on MV4-11 cell growth PMC6130198
tdTOMp16+ bone marrow mesenchymal stem cells 10 nM 10 days Inhibition of Fgr kinase activity, reduction of fibrosis biomarker expression PMC8585734

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Radiation-induced pulmonary fibrosis model Oral gavage 10 mg/kg 3 times a week for 4 weeks TL02-59 significantly reduced radiation-induced pulmonary fibrosis, decreased the expression of pro-fibrotic genes (Tgf-β, Ctgf, Collagen 1a1, Collagen 3, Collagen 4), and reduced the infiltration of CD11b+ macrophages into the lungs PMC10352363
Mice MV4-11 AML cell xenograft model Oral 1 and 10 mg/kg Once daily for three weeks Evaluate the efficacy of TL02-59 in a mouse AML model PMC6130198

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.64mL

0.33mL

0.16mL

8.20mL

1.64mL

0.82mL

16.40mL

3.28mL

1.64mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories